NCT07173855 Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
| NCT ID | NCT07173855 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Scarborough General Hospital |
| Condition | Critical Illness |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,253 participants |
| Start Date | 2025-11-25 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 3,253 participants in total. It began in 2025-11-25 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The main question this study aims to answer is whether magnesium supplementation protocols targeting a higher or lower level lead to better 30-day survival and less atrial fibrillation. Participants will not have to do any specific tasks, undergo any additional tests, or complete any surveys.
Eligibility Criteria
Inclusion Criteria: * Age 16 years or older * Admission orders written to a medical-surgical intensive care unit at a participating site * Magnesium replacement protocol ordered Exclusion Criteria: * Prior enrollment in or withdrawal from MAGNOLIA trial * Sustained ventricular tachycardia * Pre-eclampsia * Myasthenia gravis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07173855 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07173855 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07173855 currently recruiting?
Yes, NCT07173855 is actively recruiting participants. Contact the research team at jcraig@shn.ca for enrollment information.
Where is the NCT07173855 trial being conducted?
This trial is being conducted at Ajax, Canada, Bowmanville, Canada, Oshawa, Canada, Toronto, Canada and 2 additional locations.
Who is sponsoring the NCT07173855 clinical trial?
NCT07173855 is sponsored by Scarborough General Hospital. The trial plans to enroll 3,253 participants.